SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY)
INCY 61.23-1.4%Mar 26 3:59 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: scaram(o)uche8/29/2013 5:15:57 PM
1 Recommendation

Recommended By
quantman

  Read Replies (3) of 3202
 
c-MET inhibitor (INC280, entered phase II for hepatocellular carcinoma in April) is entering at least two new Novartis trials, including recurrent glioblastoma with a pan-pi3k inhibitor.......

clinicaltrials.gov

and in combo with a b-raf inhibitor, melanoma.....

clinicaltrials.gov

There's also a new U.C. Davis/NCI study, with tarceva in nsclc. A list of all trials at CT.gov listed under "INC280"....

clinicaltrials.gov
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News